Kidswell Bio Yönetim

Yönetim kriter kontrolleri 1/4

Kidswell Bio CEO'su Shinya Kurebayashi, Jun2023 tarihinde atandı, in görev süresi 1.42 yıldır. şirketin hisselerinin 0.21% doğrudan sahiptir ve bu hisselerin değeri ¥ 10.53M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.1 yıldır.

Anahtar bilgiler

Shinya Kurebayashi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.4yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Shinya Kurebayashi (48 yo)

1.4yrs

Görev süresi

Shinya Kurebayashi served as Chief Business Officer at Kidswell Bio Corporation (formerly known as Gene Techno Science Co.,Ltd.) since March 2019 until 2023 and was its Corporate Officer of Business Develo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shinya Kurebayashi	President	1.4yrs	Veri yok	0.21% ¥ 10.5m
Yasuyuki Mitani	Chief Scientific Officer & Director	1.8yrs	Veri yok	0.017% ¥ 823.0k
Munechika Sakabe	Chief Manufacturing Officer	1.8yrs	Veri yok	Veri yok
Masayuki Kawakami	Chief Development Officer & Director	1.8yrs	Veri yok	0.0062% ¥ 302.5k

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4584 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shinya Kurebayashi	President	1.4yrs	Veri yok	0.21% ¥ 10.5m
Yasuyuki Mitani	Chief Scientific Officer & Director	less than a year	Veri yok	0.017% ¥ 823.0k
Masayuki Kawakami	Chief Development Officer & Director	1.8yrs	Veri yok	0.0062% ¥ 302.5k
Masato Mori	Outside Audit & Supervisory Board	14.1yrs	Veri yok	0.0020% ¥ 96.9k
Norikazu Eiki	Independent Outside Director	6.4yrs	Veri yok	Veri yok
Hiroshi Shinagawa	Outside Audit & Supervisory Board Member	4.4yrs	Veri yok	0.054% ¥ 2.7m
Osamu Sugawara	Full-time Audit & Supervisory Board Member	4.4yrs	Veri yok	Veri yok
Sachiko Nishioka	Director	less than a year	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4584 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Kidswell Bio Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kidswell Bio Corporation, Annual General Meeting, Jun 26, 2024

Kidswell Bio Corporation, Annual General Meeting, Jun 29, 2023

Insufficient new directors

Kidswell Bio Corporation, Annual General Meeting, Jun 27, 2022

Insufficient new directors

Recent updates

Kidswell Bio Corporation to Report Q2, 2025 Results on Nov 12, 2024

New major risk - Share price stability

Kidswell Bio Corporation to Report Q1, 2025 Results on Aug 14, 2024

Kidswell Bio Corporation, Annual General Meeting, Jun 26, 2024

Kidswell Bio Corporation to Report Fiscal Year 2024 Results on May 14, 2024

New minor risk - Share price stability

Kidswell Bio Corporation to Report Q3, 2024 Results on Feb 07, 2024

New major risk - Financial data availability

New minor risk - Shareholder dilution

Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc.

New minor risk - Share price stability

New major risk - Financial data availability

Kidswell Bio Corporation, Annual General Meeting, Jun 29, 2023

Kidswell Bio Corporation to Report Q3, 2023 Results on Feb 07, 2023

Insufficient new directors

Kidswell Bio Corporation to Report Q2, 2023 Results on Nov 08, 2022

Kidswell Bio Corporation to Report Q1, 2023 Results on Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kidswell Bio Corporation, Annual General Meeting, Jun 27, 2022

Price target increased to JP¥1,840

Insufficient new directors

Kidswell Bio Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: JP¥4.87 loss per share (vs JP¥15.71 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥10.50 loss per share (vs JP¥8.69 loss in 1Q 2021)

Forecast to breakeven in 2023

Full year 2021 earnings released: JP¥34.77 loss per share (vs JP¥265 loss in FY 2020)

Third quarter 2021 earnings released: EPS JP¥0.90 (vs JP¥12.37 loss in 3Q 2020)

New 90-day high: JP¥582

Gene Techno Science Co.,Ltd. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: JP¥508

Price target raised to JP¥1,840

Dojin Group Co., Ltd. entered into a share transfer agreement to acquire Advanced Cell Technology and Engineering Ltd. from Gene Techno Science Co.,Ltd. (TSE:4584) for ¥0.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş